

SELECT PUBLICATIONS

- Bachelot T et al. **TAMRAD: A GINECO randomized Phase II trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to aromatase inhibitors (AI).** San Antonio Breast Cancer Symposium 2010;**Abstract S1-6.**
- Baselga J et al. **Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.** *N Engl J Med* 2012;366(6):520-9.
- Baselga J et al. **Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.** *N Engl J Med* 2012;366(2):109-19.
- Cortés J et al. **Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: Activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.** *J Clin Oncol* 2012;30(14):1594-600.
- Cortés J et al. **Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study.** *Lancet* 2011;377(9769):914-23.
- Gianni L et al. **First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC).** San Antonio Breast Cancer Symposium 2011;**Abstract S4-8.**
- Gianni L et al. **Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer.** *J Clin Oncol* 2010;28(7):1131-7.
- Gradishar WJ. **HER2 therapy — An abundance of riches.** *N Engl J Med* 2012;366(2):176-8.
- Hurvitz S et al. **Trastuzumab emtansine (T-DM1) versus trastuzumab plus docetaxel (H + T) in previously untreated HER2-positive metastatic breast cancer (MBC): Primary results of a randomized, multicenter, open-label, phase II study (TDM4450g/BO21976).** *Proc EMCC* 2011;**Abstract 5001.**
- Isakoff SJ et al. **A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer.** *Proc ASCO* 2010;**Abstract 1019.**
- Lehmann BD et al. **Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.** *J Clin Invest* 2011;121(7):2750-67.
- Martinez de Dueñas E et al. **Prospective evaluation of the conversion rate of HER2, ER and PR between primary tumors and corresponding metastases. CONVERTHER/GEICAM 2009-03 study.** San Antonio Breast Cancer Symposium 2011;**Abstract P2-12-17.**
- Mehta RS et al. **A Phase III randomized trial of anastrozole versus anastrozole and fulvestrant as first-line therapy for postmenopausal women with metastatic breast cancer: SWOG S0226.** San Antonio Breast Cancer Symposium 2011;**Abstract S1-1.**
- Miller KD et al. **PARP inhibition after preoperative chemotherapy in patients with triple-negative breast cancer (TNBC) or known BRCA 1/2 mutations: Hoosier Oncology Group BRE09-146.** San Antonio Breast Cancer Symposium 2011;**Abstract OT3-01-05.**
- Mirtsching B et al. **A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer.** *Clin Breast Cancer* 2011;11(2):121-8.
- Montero AJ et al. **Nab-paclitaxel in the treatment of metastatic breast cancer: A comprehensive review.** *Expert Rev Clin Pharmacol* 2011;4(3):329-34.
- Montero AJ, Vogel C. **Fighting fire with fire: Rekindling the bevacizumab debate.** *N Engl J Med* 2012;366(4):374-5.
- Paterson AHG et al. **NSABP protocol B-34: A clinical trial comparing adjuvant clodronate vs placebo in early stage breast cancer patients receiving systemic chemotherapy and/or tamoxifen or no therapy — Final analysis.** San Antonio Breast Cancer Symposium 2011;**Abstract S2-3.**
- Solin LJ. **Selecting individualized treatment for patients with ductal carcinoma in situ of the breast: The search continues.** *J Clin Oncol* 2012;30(6):577-9.
- Yardley DA et al. **Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer.** *Clin Breast Cancer* 2011;11(5):297-305.